Institute Of Hematology & Blood Diseases Hospital, China

This study tested whether the drug eltrombopag could safely raise platelet counts in adults who have both immune thrombocytopenia (a bleeding disorder with low platelets) and chronic hepatitis B virus infection. Forty-eight participants took the daily pill for 6 weeks, with some …

This early-stage study tested a new type of CAR-T cell therapy called C-CAR066 in a small group of patients with an aggressive form of lymphoma (DLBCL) whose cancer had come back after they had already received a different CAR-T treatment. The main goals were to check if the trea…

This study tested a daily pill called lusutrombopag in Chinese adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, increasing bleeding risk. The goal was to see if the drug could safely raise and maintain platele…

This small, early-stage study tested a new type of personalized immune therapy called C-CAR088 in patients whose multiple myeloma had returned or stopped responding to standard treatments. Doctors collected and genetically modified each patient's own T-cells to target a protein (…

This study looked back at two different treatment programs for children with acute myeloid leukemia (AML), a serious blood cancer. Researchers compared outcomes from 320 children treated between 2009-2015 with a newer, more intensive chemotherapy approach to those treated with an…

This study tested whether a combination of oral drugs (thalidomide, cyclophosphamide, and dexamethasone) could effectively treat newly diagnosed Waldenström Macroglobulinemia, a rare blood cancer. It involved 44 patients who had not received standard treatments. The goal was to s…

This early-phase trial tested a new treatment called CAR-T cell therapy for patients whose B-cell lymphoma had returned or stopped responding to standard treatments. Doctors collected and genetically modified the patients' own immune cells to better target and fight the cancer ce…

This study aimed to see if a patient's own stem cells, collected and transplanted back after high-dose chemotherapy, works better than standard chemotherapy alone for people with high-risk Waldenström macroglobulinemia, a rare blood cancer. It involved 70 patients in China who ha…

This study tested a two-drug combination (bortezomib and dexamethasone) for adults with a rare blood disorder called acquired pure red cell aplasia, where the body stops making enough red blood cells. It was specifically for patients whose first treatment didn't work or stopped w…

This study compared two treatment combinations to eliminate harmful antibodies in people with acquired hemophilia A, a rare bleeding disorder. Sixty-six Chinese patients received either steroids with rituximab or steroids with cyclophosphamide. Researchers measured which combinat…

This study tested two different low-dose treatment schedules of the drug rituximab for adults with immune thrombocytopenia (ITP), a condition where the immune system attacks blood platelets. Researchers compared giving 100 mg weekly for four weeks versus a single larger dose to s…

This study compared two different drug combinations for treating newly diagnosed Waldenström macroglobulinemia, a rare and slow-growing blood cancer. It involved 35 patients across multiple hospitals in China. The goal was to see which combination was better at controlling the di…

This study tested a combination of three oral drugs—zanubrutinib, ixazomib, and dexamethasone—for people newly diagnosed with symptomatic Waldenström Macroglobulinemia, a rare blood cancer. The goal was to see if this time-limited regimen (given for up to 24 months) could achieve…

This study tested a specific combination of three drugs to treat severe aplastic anemia, a rare condition where the bone marrow stops making enough blood cells. The treatment was given to 40 newly diagnosed patients who were not candidates for a bone marrow transplant. Researcher…

This study tested two different chemotherapy combinations, with or without the drug rituximab, to treat younger patients (age 65 or under) newly diagnosed with mantle cell lymphoma, a type of blood cancer. It aimed to see which approach was better at controlling the disease and k…

This study tested adding the drug dasatinib to standard chemotherapy for adults newly diagnosed with a fast-growing type of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal was to see if this combination was effective and toler…

This study tested a new type of personalized immune therapy called BZ019 (a CAR-T cell therapy) in adults with aggressive B-cell lymphomas that had returned or stopped responding to standard treatments. The main goals were to find a safe dose and see if the therapy could shrink t…

This early-stage study tested the safety of a new treatment using lab-grown natural killer (NK) immune cells in adults with acute myeloid leukemia (AML) that has returned or is hard to treat, or who have minimal traces of disease. The main goal was to see if the treatment was saf…

This was a very early, exploratory study to check the safety of a new type of cell therapy called LILRB4 STAR-T cells in adults with a specific form of leukemia that has not responded to other treatments. Only one patient was enrolled to receive the treatment after a short course…

This early study tested a one-time gene therapy called ET-01 in three young patients with severe transfusion-dependent thalassemia. The goal was to see if modifying a patient's own blood stem cells could help their body produce healthy hemoglobin, reducing or eliminating the need…

This study looked at whether the drug posaconazole, given as a tablet, can safely prevent serious lung fungal infections in patients who have received a stem cell transplant. It followed 360 transplant patients in China for about 3 months each, checking their blood drug levels an…

This study looked back at medical records to understand how the COVID-19 pandemic affected a serious fungal infection called mucormycosis in people with blood cancers. Researchers compared 60 patients from before and during the pandemic to see if infection rates, diagnosis method…